BACKGROUND Dose reduction of non-vitamin K antagonist oral anticoagulants (NOACs) is indicated in patients with
Recent registry data suggest that inappropriate NOAC dosing is not uncommon. In ORBIT-AF (Outcomes Registry for Better Informed Treatment of Atrial Fibrillation), more than one-half of the dabigatran-treated patients with creatinine clearance (CrCl) #30 ml/min received the standard dose, whereas 11% of patients with CrCl >30 ml/min received the reduced dose (8) . In XANTUS (Xarelto for Prevention of Stroke in Patients with Atrial Fibrillation), a Phase IV observational study of patients with AF prescribed rivaroxaban, more than one-third of patients with CrCl <50 ml/min received the standard dose, whereas 15% of patients with CrCl $50 ml/min received the reduced dose (9) . Although these registries provide some important insights, they are still selective (e.g., patients enrolled were mostly treated by specialists) (10) ; thus, they may have underestimated the extent of inappropriate dosing in everyday clinical practice. Furthermore, few data exist on how potential underdosing or overdosing affects the effectiveness or safety of these drugs.
Therefore, the goal of the present study was to investigate patterns of NOAC dosing and the associated risks of stroke and major bleeding in a large heterogeneous cohort of patients with AF initiating NOACs in routine clinical practice.
Specifically, we examined the use and outcomes of a standard dose in patients with a renal indication for dose reduction (potential overdosing), as well as the use and outcomes of a reduced dose in patients with no renal indication for dose reduction (potential underdosing). We hypothesized that overdosing may be related to worse safety (a higher risk of major bleeding) and underdosing may be related to worse effectiveness (a higher risk of ischemic stroke or systemic embolism).
METHODS
This retrospective analysis was conducted by using administrative claims and linked laboratory data from OptumLabs Data Warehouse, which contains >100 The present study was exempt by the Mayo Clinic
Institutional Review Board for approval because only pre-existing, de-identified data were used.
RENAL FUNCTION AND INDICATION FOR DOSE
REDUCTION. The most recent SCr levels within 1 year before treatment initiation were abstracted. We calculated eGFR by using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation (13) .
Patients were considered to have a renal indication for dose reduction if they were prescribed dabigatran and had an eGFR <30 ml/min/1.73 m 2 , rivaroxaban and an eGFR <50 ml/min/1.73 m 2 , or apixaban and an SCr level $1.5 mg/dl. The indication for dose reduction with apixaban (per the approved product label) is more complex than our criteria and requires 2 of the following 3 criteria: age $80 years, weight #60 kg, and SCr level $1.5 mg/dl. Because weight is not available in our database, our main analyses relied on SCr level as the apixaban dose indication. Numerous sensitivity tests were conducted to vary the definition of indication for dose reduction; these tests are described later along with all other sensitivity analyses.
We considered drug interactions with P-glycoprotein and cytochrome P450 3A4 inhibitors based on European Heart Rhythm Association guidelines (6). We did not include use of these medications in the criteria for dose reduction because they are generally considered were assessed. Also assessed were the percentages of patients with no renal indication but receiving reduced dose NOACs (potential underdosing).
Propensity score matching was used to balance the differences in baseline characteristics between patients receiving a reduced dose versus a standard dose. A propensity score (the probability of receiving a reduced dose) was estimated by using logistic regression based on 50 baseline characteristics, including sociodemographic characteristics, comorbidities, and concomitant medication use. Nearest neighborhood caliper matching was used to match patients based on the logit of the propensity score using a caliper equal to 0.2 of the SD of the logit of the propensity score (14) . In patients with a renal indication for dose reduction, 1:1 matching without replacement was used because the numbers of patients receiving a standard or reduced dose were similar. In patients without a renal indication for dose reduction, 1:5 propensity score matching with replacement was used because there were more patients who received a standard dose than a reduced dose.
Among apixaban-treated patients (the group with the smallest percentage of patients receiving a standard dose), the ratio of patients receiving a standard dose versus a reduced dose was approximately 5. A weight was calculated and used in the analyses to account for the larger size of the standard dose groups and the possibility some patients in the standard dose groups were used as control subjects multiple times (15) . Therefore, in the tables and figures of the Results, the number of patients receiving a standard dose was the weighted number of patients, equal to the number of patients receiving a reduced dose.
Standardized difference was used to assess the balance of covariates after matching, and a standardized difference <10% was considered acceptable (16) . If a covariate was not balanced, we examined whether including it in the regression affected results.
Cox proportional hazards regression was used to compare stroke and bleeding outcomes in each propensity score-matched cohort, with robust sandwich estimates to account for the clustering within matched sets (17) . NOAC dose was the only exposure variable included in the regression. In the analysis of patients with a renal indication for dose reduction, because of the small number of patients, we pooled the 3 NOACs for the main analysis to increase power, but patients were exact-matched on the NOACs. In the analysis of patients without a renal indication for dose reduction, each drug was examined separately. The proportional hazard assumption was tested on the basis of Schoenfeld residuals (18) and was valid for all outcomes. Third, we used inverse probability of treatment weighting instead of propensity score matching
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Fourth, because factors such as age, sex, drug interactions, and baseline risk of bleeding measured by using the HAS-BLED (hypertension, abnormal renal and liver function, stroke, bleeding, labile international normalized ratios, elderly, and drugs or alcohol) score may also affect the decision to reduce dose, we conducted subgroup analyses on the basis of these factors.
Fifth, in the main analyses of patients with a renal indication for dose reduction, we pooled 3 NOACs because of the small sample size. Additional analyses were performed by examining the outcomes associated with using standard doses versus reduced doses for each medication separately.
Sixth, intracranial bleeding was examined in each propensity score-matched cohort, which was not included in the main analyses due to the small number of events.
Lastly, we repeated the analyses by using 3 pre-specified falsification endpoints; these endpoints were inpatient admission due to sepsis, pneumonia, and chronic obstructive pulmonary disease, which are outcomes unlikely to occur as a result of NOAC dose reduction. This method can provide some insights on whether there is residual confounding after propensity score matching (20) .
Further details of the methods are provided in the Online Appendix. All analyses were conducted by using SAS version 9. score was 2 (IQR: 2 to 3) ( Table 1) . Patients were followed up for a median of 4.0 months (IQR: 1.0 to 9.6 months).
The detailed follow-up data according to drug and indication for dose reduction, as well as patient characteristics before and after propensity score matching, are presented in Online Tables 3 to 7 .
Among patients with a renal indication for dose reduction, 43.0% received standard doses (Figure 1 ).
Among patients with no renal indication for dose reduction, 13.3% received reduced doses (Figure 2 ). (Figure 4) .
Results from all sensitivity and subgroup analyses were generally consistent with the main analysis (Online Tables 12 to 25 ). For instance, when inverse probability of treatment weighting was used instead of propensity score matching, potential overdosing was associated with a higher risk of major bleeding (HR: 2.24; 95% CI: 1.18 to 4.24 for the 3 NOACs pooled), with a similar risk of stroke (Online Table 17 ).
Potential underdosing of apixaban was associated with a nonsignificant trend toward higher risk of stroke but a similar risk of major bleeding;
conversely, potential underdosing of rivaroxaban was associated with a nonsignificant trend toward lower risk of stroke (Online Table 18 ). Additional data, such as types of major bleeding and cumulative risks, can be found in Online It might be surprising that >40% of patients with a renal indication for dose reduction did not receive a reduced dose, but our results are consistent with previous U.S. and international studies (8, 9) . In patients with a renal indication for dose reduction, 
0.03
Among patients with a renal indication for dose reduction, event rates for ischemic stroke and systemic embolism (S/SE) and major bleeding and hazard ratios comparing a standard dose versus a reduced dose non-vitamin K antagonist oral anticoagulant (potential overdosing effect) favored the reduced dose. CI ¼ confidence interval. 
0.76
Among patients without a renal indication for dose reduction, event rates for S/SE and major bleeding and hazard ratios comparing a reduced dose versus a standard dose non-vitamin K antagonist oral anticoagulant (potential underdosing effect) favored the standard dose.
Abbreviations as in Figure 3 . Abbreviations as in Table 2 .
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Several recent NOAC studies reported a mean followup of #6 months (23) (24) (25) (26) (27) . This outcome is likely due to poor adherence to treatment in routine practice (28) and thus does not necessarily limit the generalizability of our results. Furthermore, a short follow-up Lastly, the number of events and the event rates were low; therefore, the findings should be viewed as hypothesis-generating and need to be confirmed by future studies. yao.xiaoxi@mayo.edu.
R E F E R E N C E S

